Tesamorelin studies
97 journal papers mention Tesamorelin in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Tesamorelin is safe, effective or approved for any use.
- Papers
- 97
- 82 articles, 15 reviews
- Earliest paper
- 2007
- Most papers in 2026 (14)
- Open access
- 58%
- free to read somewhere
- Reviews
- 15%
- of all papers listed
What kind of studies
Of 95 papers in PubMed that mention Tesamorelin in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials21
- Other clinical trials2
- Meta-analyses and systematic reviews3
- Other reviews33
- Case reports2
- Animal studies only1
- Studies in humans76
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Tesamorelin in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 24
- Completed
- 14
- Ongoing or planned
- 3
- Phase 1
- 2
- Phase 2
- 10
- Phase 3
- 2
- Body Composition and Adipose Tissue in HIV
NCT03226821TerminatedPhase 4started 2018-02-07
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
NCT06554717RecruitingPhase 2started 2025-07-10
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
NCT07481734RecruitingPhase 2started 2026-02-02
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
NCT02572323CompletedPhase 2started 2017-02-15
- Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
NCT03375788CompletedPhase 2started 2019-01-17
The five most recently updated studies. See all 24 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2007 to 2026, peak 14 papers in a year. The latest year may still be incomplete.
Where it is published
- The Journal of Clinical Endocrinology & Metabolism5 papers
- AIDS5 papers
- Open Forum Infectious Diseases4 papers
- Growth Hormone & IGF Research4 papers
- Clinical Infectious Diseases4 papers
The papers
Most citedName in the title
- Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data
Julian Falutz, Jean‐Claude Mamputu, Diane Potvin et al. · The Journal of Clinical Endocrinology & Metabolism · 2010
Study in humans98 citations
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Takara Leah Stanley, Lindsay T. Fourman, Meghan N. Feldpausch et al. · The Lancet HIV · 2019
Randomized trialOpen access86 citationsRead the open copy →
- Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation
Takara Leah Stanley, Meghan N. Feldpausch, Jin-Hee Oh et al. · JAMA · 2014
Randomized trialOpen access85 citationsRead the open copy →
- Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension
Julian Falutz, Diane Potvin, Jean‐Claude Mamputu et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010
Randomized trial77 citations
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Julian Falutz, Soraya Allas, Jean‐Claude Mamputu et al. · AIDS · 2008
Randomized trial65 citations
- Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin
Takara Leah Stanley, Julian Falutz, Christian Marsolais et al. · Clinical Infectious Diseases · 2012
Randomized trial · Phase 3Open access29 citationsRead the open copy →
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Lindsay T. Fourman, James M. Billingsley, George Agyapong et al. · JCI Insight · 2020
Randomized trialOpen access · CC BY25 citationsRead the open copy →
- Tesamorelin
Sohita Dhillon · Drugs · 2011
Review24 citations
- Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy
Linda M. Spooner, Jacqueline L. Olin · Annals of Pharmacotherapy · 2012
Review23 citations
- Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
David R. Clemmons, Sam S. Miller, Jean‐Claude Mamputu · PLoS ONE · 2017
Randomized trialOpen access · CC BY19 citationsRead the open copy →
- Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction
Takara Leah Stanley, Julian Falutz, Jean‐Claude Mamputu et al. · AIDS · 2011
Randomized trial · Phase 3Open access17 citationsRead the open copy →
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
Roger G. Bedimo · HIV/AIDS - Research and Palliative Care · 2011
Open access · CC BY-NC15 citationsRead the open copy →
- The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
Stefan Adrian, Ann L. Scherzinger, Abanti Sanyal et al. · The Journal of Frailty & Aging · 2019
Randomized trialOpen access · CC BY-NC-ND13 citationsRead the open copy →
- Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach
Lindsay T. Fourman, Takara Leah Stanley, James M. Billingsley et al. · Scientific Reports · 2021
Study in humansOpen access · CC BY11 citationsRead the open copy →
- Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV
Lindsay T. Fourman, Natalia Czerwonka, Meghan N. Feldpausch et al. · AIDS · 2017
Study in humansOpen access11 citationsRead the open copy →
- The Effects of Tesamorelin on Phosphocreatine Recovery in Obese Subjects With Reduced GH
Hideo Makimura, Caitlin A. Murphy, Meghan N. Feldpausch et al. · The Journal of Clinical Endocrinology & Metabolism · 2013
Randomized trialOpen access11 citationsRead the open copy →
- Tesamorelin, a human growth hormone releasing factor analogue
Ying Wang, Brian Tomlinson · Expert Opinion on Investigational Drugs · 2009
Review11 citations
- Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat
Alexandra Mangili, Julian Falutz, Jean‐Claude Mamputu et al. · PLoS ONE · 2015
Randomized trialOpen access · CC BY9 citationsRead the open copy →
- Tesamorelin, liver fat, and NAFLD in the setting of HIV
Jennifer Audsley, Joe J Sasadeusz, Sharon R. Lewin · The Lancet HIV · 2019
Study in humans7 citations
- Tesamorelin improves fat quality independent of changes in fat quantity
Jordan E. Lake, Kristen La, Kristine Mace Erlandson et al. · AIDS · 2021
Study in humansOpen access5 citationsRead the open copy →
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Samuel C Russo, Mollie W Ockene, Allison K Arpante et al. · AIDS · 2024
Randomized trialOpen access4 citationsRead the open copy →
- Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects
Mario González‐Sales, Olivier Barrière, Pierre‐Olivier Tremblay et al. · Clinical Pharmacokinetics · 2014
Randomized trial · Phase 14 citations
- Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy
Gracia María Mateo, María del Mar Gutiérrez, Peré Domingo · Expert Review of Endocrinology & Metabolism · 2010
4 citations
- Impact of Tesamorelin, a Growth Hormone‐Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers
Shirley Teng, Diane Potvin, Jean‐Claude Mamputu et al. · Clinical Pharmacology in Drug Development · 2013
3 citations
- Tesamorelin: A hope for ART-induced lipodystrophy
Akash Patel, Hardik Gandhi, Aman Upaganlawar · Journal of Pharmacy And Bioallied Sciences · 2011
Open access · CC BY-NC-SA3 citationsRead the open copy →
- Tesamorelin: A novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue
Julian Falutz · Drugs of today · 2011
Study in humans3 citations
- FDA approves tesamorelin for HIV-related lipodystrophy
Kate Traynor · American Journal of Health-System Pharmacy · 2010
Study in humans3 citations
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
A Badran, Abdulrhman Helal, Karim Samir Shata et al. · Obesity Research & Clinical Practice · 2026
Meta-analysis2 citations
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Ronald J. Ellis, Florin Vaida, Keren Hu et al. · The Journal of Infectious Diseases · 2025
Randomized trial · Phase 2Open access · CC BY2 citationsRead the open copy →
- O3‐07‐08: Tesamorelin, a growth hormone‐releasing hormone analogue, improves cognitive function in MCI and healthy aging: Results of a randomized controlled trial
Laura D. Baker, Soo Borson B, George R. Merriam et al. · Alzheimer s & Dementia · 2011
Open access2 citationsRead the open copy →
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
Kristine Mace Erlandson, Laurel Gustafson, Julia E Johnson et al. · BMJ Open · 2026
Study in humansOpen access · CC BY-NC1 citationsRead the open copy →
- Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Robin Beach, Zandraetta Tims-Cook, Colleen S. McGary et al. · Clinical Infectious Diseases · 2026
Case report1 citations
- Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
Farah Rahman, Taryn A. McLaughlin, Pedro Mesquita et al. · Journal of Clinical and Translational Science · 2022
Open access · CC BY1 citationsRead the open copy →
- Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects
Mario González‐Sales, Olivier Barrière, Pierre‐Olivier Tremblay et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2015
Clinical trial · Phase 11 citations
- Tesamorelin for the treatment of excess abdominal fat in HIV-infected individuals with lipodystrophy
Giovanni Guaraldi, Chiara Stentarelli, J Faluz · Clinical Investigation · 2013
Open access · CC BY1 citationsRead the open copy →
- Tesamorelin can improve cognitive function
Andy McLarnon · Nature Reviews Endocrinology · 2012
1 citations
- OR2,10 Metabolic effects of tesamorelin, a growth hormone-releasing hormone analogue, in HIV-infected patients with excess abdominal fat: a pooled analysis of 2 multicenter, randomized, placebo-controlled phase 3 trials
Julian Falutz, Jean‐Claude Mamputu, Diane Potvin et al. · Growth Hormone & IGF Research · 2010
1 citations
- TESAMORELIN AMONG GROWTH HORMONE SECRETAGOGUE PEPTIDES: A COMPARATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, VISCERAL FAT REDUCTION, ENDOCRINE SELECTIVITY, AND SAFETY
Luiz Felippe Mendes Caquetti · INTERNATIONAL BLEST SCIENTIFIC · 2026
Open accessRead the open copy →
- TIRZEPATIDE, ELAMIPRETIDE (SS-31), TESAMORELIN AND BREMELANOTIDE: MECHANISTIC FOUNDATIONS, CLINICAL EVIDENCE AND THERAPEUTIC APPLICATIONS IN METABOLIC, MITOCHONDRIAL AND NEUROENDOCRINE CONTEXTS
Luiz Felippe Mendes Caquetti · INTERNATIONAL BLEST SCIENTIFIC · 2026
Open accessRead the open copy →
- P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants
Christian Caldji, Christian Marsolais, Éric Sicard et al. · Open Forum Infectious Diseases · 2026
Open access · CC BYRead the open copy →
LatestName in title or abstract
- Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review
V Vasylieva, Annette West, Edward Karpman · Sexual Medicine Reviews · 2026
Review
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
Kristine Mace Erlandson, Laurel Gustafson, Julia E Johnson et al. · BMJ Open · 2026
Study in humansOpen access · CC BY-NC1 citationsRead the open copy →
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Aleksander Dominikowski, Zofia Rękoś, Michał Olejarz et al. · Frontiers in Endocrinology · 2026
ReviewOpen access · CC BY1 citationsRead the open copy →
- The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment
Courtney Elaine Stewart, Kaci P. French, Traver J. Wright et al. · eNeurologicalSci · 2026
Open access · CC BY-NC-NDRead the open copy →
- TESAMORELIN AMONG GROWTH HORMONE SECRETAGOGUE PEPTIDES: A COMPARATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, VISCERAL FAT REDUCTION, ENDOCRINE SELECTIVITY, AND SAFETY
Luiz Felippe Mendes Caquetti · INTERNATIONAL BLEST SCIENTIFIC · 2026
Open accessRead the open copy →
- Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Robin Beach, Zandraetta Tims-Cook, Colleen S. McGary et al. · Clinical Infectious Diseases · 2026
Case report1 citations
- TIRZEPATIDE, ELAMIPRETIDE (SS-31), TESAMORELIN AND BREMELANOTIDE: MECHANISTIC FOUNDATIONS, CLINICAL EVIDENCE AND THERAPEUTIC APPLICATIONS IN METABOLIC, MITOCHONDRIAL AND NEUROENDOCRINE CONTEXTS
Luiz Felippe Mendes Caquetti · INTERNATIONAL BLEST SCIENTIFIC · 2026
Open accessRead the open copy →
- Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss
Gunjan Arora, Katherine R. Conde, Cyrus V Desouza · Journal of Clinical Medicine · 2026
ReviewOpen access · CC BY7 citationsRead the open copy →
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Omar F. Rahman, Steven J. Lee, William A. Seeds · JAAOS Global Research and Reviews · 2026
ReviewOpen access · CC BY-NC-ND5 citationsRead the open copy →
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Cory K. Mayfield, Ioanna K. Bolia, Cailan L Feingold et al. · The American Journal of Sports Medicine · 2026
Review12 citations
- P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants
Christian Caldji, Christian Marsolais, Éric Sicard et al. · Open Forum Infectious Diseases · 2026
Open access · CC BYRead the open copy →
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
A Badran, Abdulrhman Helal, Karim Samir Shata et al. · Obesity Research & Clinical Practice · 2026
Meta-analysis2 citations
- Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model
Boniface Mwangi Chege, Peter Waweru Mwangi, Charles Githua Githinji et al. · Brazilian Journal of Medical and Biological Research · 2026
Animal studyOpen access · CC BYRead the open copy →
- Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis
Aqsa Mohammed Ditta, Ruqaiya Muhammad Naeem, Muhammad Mohsin Sami et al. · Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2026
Meta-analysisOpen access · CC BY-NCRead the open copy →
- (197) Peptides in Practice: Evaluating Efficacy and Safety in Men’s Health
R Arora, Arjun K. Venkatesh, Gene Austin Krishingner et al. · The Journal of Sexual Medicine · 2025
Open accessRead the open copy →
- Metabolic dysfunction-associated steatotic liver disease in people with HIV
Arijeet K. Gattu, Lindsay T. Fourman · Current Opinion in HIV and AIDS · 2025
ReviewOpen access9 citationsRead the open copy →
- Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study
Andrew Mihalache, Emily Volfson, Ryan S. Huang et al. · Cureus · 2025
Open access · CC BY2 citationsRead the open copy →
- P-433. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis
Steven Kyle Grinspoon, Lindsay T. Fourman, Takara Leah Stanley et al. · Open Forum Infectious Diseases · 2025
Open access · CC BYRead the open copy →
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Ronald J. Ellis, Florin Vaida, Keren Hu et al. · The Journal of Infectious Diseases · 2025
Randomized trial · Phase 2Open access · CC BY2 citationsRead the open copy →
- Reducing Cardiovascular Risk in HIV: The Unseen Impact of Visceral Fat
Eleanor Roberts · Microbiology & infectious diseases : · 2024
Open access · CC BY-NCRead the open copy →
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Samuel C Russo, Mollie W Ockene, Allison K Arpante et al. · AIDS · 2024
Randomized trialOpen access4 citationsRead the open copy →
- Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome
Boniface Mwangi Chege, Peter Waweru Mwangi, Charles Githua Githinji et al. · PLoS ONE · 2024
Study in humansOpen access · CC BY4 citationsRead the open copy →
- 1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
Taryn A. McLaughlin, Steven Kyle Grinspoon, Takara Leah Stanley et al. · Open Forum Infectious Diseases · 2023
Open access · CC BYRead the open copy →
- HIV-associated dyslipidemia: pathogenesis and its management
Zhikai Wan, Bohao Dai, Xueling Zhu et al. · Chinese Medical Journal · 2023
Study in humansOpen access · CC BY-NC-ND11 citationsRead the open copy →
- Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
Farah Rahman, Taryn A. McLaughlin, Pedro Mesquita et al. · Journal of Clinical and Translational Science · 2022
Open access · CC BY1 citationsRead the open copy →
- Causes and outcomes of hepatic fibrosis in persons living with HIV
Debra W. Yen, Kenneth E. Sherman · Current Opinion in HIV and AIDS · 2022
Review11 citations
- Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
Julia M. Fraile, Soumya Palliyil, Caroline Jane Barelle et al. · Drug Design Development and Therapy · 2021
ReviewOpen access · CC BY-NC152 citationsRead the open copy →
- Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach
Lindsay T. Fourman, Takara Leah Stanley, James M. Billingsley et al. · Scientific Reports · 2021
Study in humansOpen access · CC BY11 citationsRead the open copy →
- Growth Hormone Releasing Hormone Reduces Plasma Markers of Immune Activation and Hepatic Immune Pathways in Nonalcoholic Fatty Liver Disease
Takara Leah Stanley, Lindsay T. Fourman, Lai Ping Wong et al. · Journal of the Endocrine Society · 2021
Open access · CC BY-NC-NDRead the open copy →
- Tesamorelin improves fat quality independent of changes in fat quantity
Jordan E. Lake, Kristen La, Kristine Mace Erlandson et al. · AIDS · 2021
Study in humansOpen access5 citationsRead the open copy →
- Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease
Takara Leah Stanley, Lindsay T. Fourman, Lai Ping Wong et al. · Clinical Infectious Diseases · 2021
Randomized trialOpen access16 citationsRead the open copy →
- 935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial
Farah Rahman, Marilyn de Chantal, Pedro Mesquita et al. · Open Forum Infectious Diseases · 2020
Open access · CC BY-NC-NDRead the open copy →
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Lindsay T. Fourman, James M. Billingsley, George Agyapong et al. · JCI Insight · 2020
Randomized trialOpen access · CC BY25 citationsRead the open copy →
- Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus–Associated Nonalcoholic Fatty Liver Disease
Lindsay T. Fourman, Takara Leah Stanley, Isabel Zheng et al. · Clinical Infectious Diseases · 2020
Randomized trialOpen access34 citationsRead the open copy →
- Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade
Thomas Eigentler, Diana Lomberg, Jürgen Machann et al. · Annals of Internal Medicine · 2020
Case report62 citations
- Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6
Allison Ross Eckard, Heather Hughes, Nancy L. Hagood et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020
Study in humansOpen access8 citationsRead the open copy →
- Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation
Timothy S. Chisholm, Sameer S. Kulkarni, Khondker Rufaka Hossain et al. · Journal of the American Chemical Society · 2019
91 citations
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Takara Leah Stanley, Lindsay T. Fourman, Meghan N. Feldpausch et al. · The Lancet HIV · 2019
Randomized trialOpen access86 citationsRead the open copy →
- Tesamorelin, liver fat, and NAFLD in the setting of HIV
Jennifer Audsley, Joe J Sasadeusz, Sharon R. Lewin · The Lancet HIV · 2019
Study in humans7 citations
- The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
Stefan Adrian, Ann L. Scherzinger, Abanti Sanyal et al. · The Journal of Frailty & Aging · 2019
Randomized trialOpen access · CC BY-NC-ND13 citationsRead the open copy →
Each list shows up to 40 papers.See all 97 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:26 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.